Mylan, Teva settle Copaxone patent fight; ViiV's new Tivicay wins key EU backing;

@FiercePharma: Monday's top story: Who leaked the scary Copaxone numbers? Teva intends to find out. Story | Follow @FiercePharma

@EricPFierce: Any who thinks women aren't controlling the destiny of biopharma would be wrong. Women in Biotech 2013 Report | Follow @EricPFierce

@CarlyHFierce: FDA withdraws restrictions on GSK diabetes drug Avandia - too little, too late? Story | Follow @CarlyHFierce

> Mylan ($MYL) and Teva Pharmaceutical Industries ($TEVA) have come to terms in a patent fight over the latter's multiple sclerosis treatment Copaxone, but those terms weren't disclosed. Report

> ViiV Healthcare's new HIV treatment Tivicay is on track for European approval with new backing from a key committee; the drug launched in the U.S. a few weeks ago. Report

> Hedge fund Elliott International has accumulated control of 25% of the voting rights in Germany-based drugs distributor Celesio, which McKesson ($MCK) is trying to buy for $8.3 billion. Report

> Valeant Pharmaceuticals ($VRX) tapped Ari Kellen to take on the role of executive vice president and company group chairman; he had been a senior partner at McKinsey & Co. Report

> Sun Pharmaceutical stock gained after its subsidiary Taro Pharmaceutical offered to buy back up to $200 million in shares, which would push Sun's effective stake in the Israeli drugmaker to 69%. Report

> A Florida judge upheld the use of a new combination of execution drugs that leaves out the chronically short pentobarbital. Report

Medical Device News

@FierceMedDev: Becton Dickinson boost its quarterly dividend. Item | Follow @FierceMedDev

@MarkHFierce: J&J's $2.5B hip implant settlement offer is already beginning to generate some flack from patients. Story via NYT | Follow @MarkHFierce

> Hospira faces another pump recall over deadly risk. Story

> Patient anger could scuttle J&J's $2.5B hip settlement. Article

> Smith & Nephew's M&A blitz rolls on with Brazilian buy. News

> Dutch VC firm readies $200M fund with an eye on device and Dx investments. More

Biotech News

@FierceBiotech: In our latest report, we feature the top women in the biotech industry. Report | Follow @FierceBiotech

@JohnCFierce: Sanofi might want to reevaluate its cancer strategy about now. Iniparib and fedratinib both written off in '13. More | Follow @JohnCFierce

@DamianFierce: Pro-23andMe petition aims to protect "potentially life-saving diagnostic kits," thereby making the FDA's case. Petition | Follow @DamianFierce

@EmilyMFierce: Harvard study: 30% of all medical tests are probably unnecessary. More | Follow @EmilyMFierce

> Bayer's $2.4B bid to buy Algeta fits neatly with cancer drug strategy. Story

> Sanofi, Merrimack rack up third straight failure for lead cancer drug. Article

> BTG wins FDA OK for varicose vein treatment, projects $500M peak. Story

Pharma Manufacturing News

> JLL expects to buy more CMOs. Story

> Glaxo piles onto API expansion in Scotland. More

> PL Developments, Aaron combine expertise in OTC manufacturing. Article

> Ranbaxy ready to bail on vaccine manufacturing. More

> Bafna draws buyout interest for its European-approved manufacturing. News

Biotech Research News

> Eli Lilly, Project A.L.S. forge preclinical drug discovery pact. News

> Biota halts preclinical antibiotics program as antimicrobial resistance grows. Report

> New targets for Parkinson's revealed in gene network. Story

> Antibiotics may weaken body's response to cancer therapies. Article

> New York Stem Cell Foundation, NIH partner to study rare diseases. Story

And Finally... The number of U.S. ADHD cases leapt by 42% from 2003 to 2012, with 11% of kids aged 4 to 17 years now diagnosed with the disorder. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.